



King Pharmaceuticals, Inc.  
400 Crossing Boulevard  
Bridgewater, New Jersey 08807  
908.429.6000  
www.kingpharm.com  
NYSE:KG

February 5, 2008

Dear Prescriber:

After careful consideration, King Pharmaceuticals, Inc. has decided to discontinue the manufacture of Humatin<sup>®</sup> Acetate (Paromomycin Sulfate Capsules, USP). This decision is based upon many factors, including medical use, availability of generic alternatives, and the cost of manufacturing and distributing products with minimal sales volume.

Humatin<sup>®</sup> will remain available through pharmacies and wholesalers until current supplies are depleted. Humatin<sup>®</sup> is distributed through Monarch Pharmaceuticals, Inc, a wholly-owned subsidiary of King Pharmaceuticals, Inc. No additional product will be available after Monarch, pharmacy, and wholesaler supplies are exhausted.

If you have any questions or concerns, you may contact our Professional Information Services Department at 800-776-3637.

Important Prescribing and Safety Information:

Humatin<sup>®</sup> (Paromomycin Sulfate Capsules, USP) is indicated for acute and chronic intestinal amebiasis and as adjunctive therapy for the management of hepatic coma.

Important Safety Information:

Paromomycin is contraindicated in individuals with an intestinal obstruction. As with other antibiotics, use of this antibiotic may result in an overgrowth of non-susceptible organisms including fungi, of which appropriate measure should be taken. Use with caution in individuals with ulcerative lesions of the bowel to avoid renal toxicity through inadvertent absorption. Nausea, abdominal cramps, and diarrhea have been reported with doses over 3 grams daily.

Sincerely,

A handwritten signature in blue ink that reads "Linda Wase".

Linda Wase, M.D.  
Executive Vice President  
Medical Affairs

*Please see accompanying full prescribing information.*